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Abstract 
Two phosphatidylinositol 4-kinase isozymes, type 3 and type 2, have been separated on hydroxylapatite after solubilizing bovine brain 
microsomes with Triton X-114. Employing a newly developed renaturation procedure following SDS-PAGE, we demonstrate hat a 200 
kDa polypeptide carries the enzymic activity of this type 3 isoform. Chromatography on hydroxylapatite, Heparin-Sepharose, Superdex 
200 and finally SDS-PAGE re:suits in an approximately 30000-fold purification. Tryptic peptides generated from the 200 kDa polypeptide 
after SDS-PAGE have been sequenced and the obtained ata have been used for constructing and synthesizing degenerated oligonucleo- 
tides. Polymerase chain reaction as well as screening of cDNA libraries allowed several clones to be isolated from which a 4.7 kb 
contiguous equence can be built up. The open reading frame covers 4.4 kb with a 0.3 kb untranslated 3' end which yields a deduced 
amino acid sequence of 1,467 amino acids. The C-terminal part of ca. 300 amino acids represents the catalytic domain. Sequence 
alignment of this domain with the mammalian counterpart, the human type 2 phosphatidylinositol 4-kinase, the yeast kinases STT4 and 
PIK1, as well as with the catalytic domains of bovine, human, mouse and yeast phosphatidylinositol 3-kinases reveals a high degree of 
identity: 26 of these approximately 300 amino acids are invariable in all of these eight catalytic domains. Five motifs indicate nuclear 
localization and DNA binding properties of the enzyme. Two leucine zipper motifs (amino acids 358-386, 862-882) are detectable. 
Furthermore, a helix loop helix motif (amino acids 716-729) as well as two nuclear localization signals (amino acids 838-854, 345-349) 
indicate the presence of the type 3 isoform in the nucleus. 
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1. Introduction 
In membranes of eukaryotic ells phosphoinositide syn- 
thesis and degradation are well known signaling events by 
which growth factors, hornaones and neurotransmitters can 
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exert their physiological effects (for review, see Refs. 
[ 1,2]). One of these signaling pathways tarts by phospho- 
rylating Ptdlns at the 4' and at the 5' position. The 
resulting product, Ptdlns(4,5)P 2, is cleaved hydrolytically 
into two second messengers,  d iacylglycerol  and 
Ins(1,4,5)P 3 by phospholipase C (for review, see Refs. 
[3,4]). An alternate signaling pathway involves a series of 
polyphosphoinositides phosphorylated at the 3' position of 
the inositol ring which gives rise to the derivatives 
Ptdlns(3)P, Ptdlns(3,4)P 2 and Ptdlns(3,4,5)P 3 (for review, 
see Ref. [5]). 
Little is known about the regulatory mechanisms of 
Ptdlns phosphorylation. Generally, when phospholipase C 
is stimulated, a fall in the Ptdlns(4)P and Ptdlns(4,5)P 2 
concentrations is followed by rapid resynthesis. There are 
indications that the Ptdlns/Ptdlns(4,5)P 2 ratio can be 
changed by activating protein kinase C or by increasing 
the cAMP level (for review, see Ref. [4]). However, the 
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complex metabolism of the polyphosphoinositides oes not 
allow these alterations to be unequivocally assigned to 
specific enzymatic steps. Moreover, Ptdlns(4)P is formed 
not only in plasma membranes but also in most internal 
membranes such as in sarcoplasmic reticular [6,7], liver 
endoplasmic reticular [8] and in lysosomal membranes [9] 
as well as in Golgi [10]. In the sarcoplasmic reticulum of 
skeletal [11] and smooth muscle [12], Ptdlns(4)P has been 
characterized as an activator of the Ca 2+ transport AT- 
Pase. Several enzymes involved in the Ptdlns cycle have 
been identified in the nucleus [13,14]. 
Enzymatically but not structurally at least two different 
Ptdlns 4-kinases have been partially characterized in mam- 
malian tissues [5,15-17]. Type 2 is a 55-kDa enzyme 
present in all animal cells, whereas the type 3 isoform 
expresses high activity in bovine and rat brain as well as in 
bovine uterus. These two Ptdlns 4-kinases, type 2 and 3, 
differ from Ptdlns 3-kinase (originally termed as type 1 
Ptdlns kinase; for review see Refs. [5,18]) in their require- 
ment of non-ionic detergent for enzyme activity and in 
their resistance to Triton X-100 inhibition up to 3%. 
Moreover, the type 2 enzyme is inhibited by adenosine ca. 
20-fold stronger than the type 3 enzyme; furthermore the 
Krn values for the substrates Ptdlns and ATP/Mg 2÷ are 
3- to 7-fold lower for the type 2 than for the type 3 
enzyme, respectively [5,15,17]. In S. cerevisiae multiple 
forms of 45 and 55 kDa have also been demonstrated and 
have been proven to be membrane-bound [19,20]; in addi- 
tion, a soluble Ptdlns 4-kinase of 125 kDa exists [21]. 
Two genes encoding Ptdlns 4-kinases were isolated 
from S. cerevisiae. A 125-kDa form, PIK1, seems to be 
indispensable to cell growth [21], whereas it has been 
suggested that STT4, the other Ptdlns 4-kinase - a 200 
kDa protein - is possibly involved in the protein kinase C 
pathway [22]. 
A human type 2 Ptdlns 4-kinase (PI4K a)  has recently 
been cloned from placental and brain libraries [23] and has 
been shown to be homologous to the yeast Ptdlns 4-kinases, 
STT4 and PIK1 [21,24], as well as to Ptdlns 3-kinase 
family genes such as bovine [25], human [26], mouse p110 
[27], and yeast Vps34 [28]. 
Here we report the first characterization f the type 3 
Ptdlns 4-kinase from bovine brain by isolating the protein, 
by characterizing its enzymological properties as well as 
by partial protein and cDNA sequencing. The protein 
contains a C-terminal catalytic domain homologous to the 
human and yeast Ptdlns 4-kinases and, surprisingly, motifs 
indicating nuclear localization. 
2. Materials and methods 
2.1. Enrichment of Ptdlns 4-kinase from bovine brain 
Step 1: Preparation of solubilized membrane fraction. 
From fresh bovine brain (100-130 g) the skin was re- 
moved and the brain was homogenized in an ultraturrax 
for 1 min in 350 ml buffer containing 10 mM Tris-HC1, 1 
mM DTE, 0.1 mM EDTA, 0.32 M saccharose, 2 mM 
benzamidine, 2 mM aminocaproic acid, 0.1 mM EGTA, 
0.1 mM PMSF, 2 /zg/ml aprotinin, 2 /xM leupeptin (pH 
7.5), and was then further disrupted in a tightly fitting 
teflon glass homogenizer (Braun-Melsungen, FRG). This 
homogenate was centrifuged at 1000 X g for 10 min and 
subsequently the supernatant (crude extract) was cen- 
trifuged at 100000 X g for 70 min. The sediment was 
resuspended in 10 mM Tris-HC1, 1 mM DTE, 0.1 mM 
EDTA (pH 7.5) (buffer A) containing 2 /xM leupeptin, 
0.9% NaC1, and again homogenized in the ultraturrax. 
Membranes were collected by centrifugation at 100 000 X g 
for 60 min and resuspended in 300 ml buffer A containing 
1 mM benzamidine, 1 mM aminocaproic acid, 0.05 mM 
EGTA, 0.05 mM PMSF, 1 /xg/ml aprotinin and 1 /xM 
leupeptin. At 2 mg protein/ml the membranes were solu- 
bilized by stirring with 0.1% (w/v) Triton X-114 at 2°C 
for 20 min according to Bordier [29]. Increasing the tem- 
perature to 30°C resulted in a phase separation which was 
accelerated by centrifugation at 15000 X g for 25 min. 
The Ptdlns 4-kinase present in the water phase (4°C) was 
precipitated with ammonium sulfate up to 30% saturation 
and collected by centrifuging it at 54 000 X g for 30 min. 
The pellet was dissolved in 5 mM Tris-HCI, 0.5 mM DTE, 
0.05 mM EDTA, 0.1% Triton X-100 (pH 7.5) and dialyzed 
overnight against he same buffer. Protease inhibitors were 
added to the dialysate to reach final concentrations of 2.5 
/zg aprotinin/ml, 0.05 mM PMSF and 2.5 /zM leupeptin. 
This preparation can be stored at -20°C for several 
months without causing a significant loss of activity. 
Step 2: Hydroxylapatite chromatography 1. The dia- 
lyzed material was adjusted to 500 mM NaC1, 0.06 mM 
EDTA and then centrifuged for 60 min at 100000 X g. 
The supernatant was applied to hydroxylapatite (diam. 5 
cm; bed volume 160 ml), pre-equilibrated with 10 volumes 
of buffer B (5 mM KH2PO4/KOH, 1 mM DTE, 500 mM 
NaC1 (pH 7.0) flow rate 180 ml/h, during elution 240 
ml/h). The column was first washed with 3500 ml of 
buffer B, and subsequently with 500 ml of buffer C (25 
mM KH2POa/KOH, 1 mM DTE, 500 mM NaC1, pH 7.0). 
The type 3 isoform was eluted with buffer D (65 mM 
KHEPO4/KOH, 1 mM DTE, 500 mM NaC1, pH 7.0). 
EGTA, aprotinin and leupeptin were added to the eluted 
enzyme to reach final concentrations of 0.5 mM, 2 /xg/ml 
and 2 /zM, respectively. The column was further washed 
with four bed volumes of buffer E (300 mM 
KHEPO4/KOH, 1 mM DTE, 500 mM KCI, pH 7.0) and 
the type 2 isoform was eluted with buffer F (0.2% Triton 
X-100 in buffer E). The pooled fractions were supplied 
with EGTA and protease inhibitors, as in the case of the 
type 3 isoform. 
Step 3: Heparin-Sepharose CL-6B chromatography of 
the type 3 isoform. The pool eluted by buffer D was 
diluted with two volumes of buffer G (10 mM Tris-HCl, 1 
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mM DTE, 0.1 mM EDTA, 5 mM MgC12, pH 7.5) and 
loaded onto a 2.6 × 11 cm Heparin-Sepharose CL-6B col- 
umn (Pharmacia-LKB, Freiburg) pre-equilibrated with 20 
bed volumes of buffer G (flow rate 120 ml/h). The 
enzyme was eluted with a NaC1 gradient consisting of 
buffer G and 1 M NaC1 in buffer G (buffer H) by using the 
following gradient programme: 0-120 ml, 0% H; 120-170 
ml, 0-30% H; 170-450 ml, 30% H; 450-750 ml, 30-60% 
H; 750-800 ml, 60-100% H; 800-900 ml, 100% H. 
Step 4: Hydroxylapatite chromatography H of the type 3 
isoform. Pooled fractions from Heparin-Sepharose chro- 
matography were applied to a second hydroxylapatite col- 
umn (1 X 6 cm, Pharmacia, HR 10/10) pre-equilibrated 
with 20 bed volumes of buffer I (5 mM KH2PO4/KOH, 1 
mM DTE, pH 7.0, flow r~.te 45 ml/h). The enzyme was 
eluted using buffer I and buffer J (350 mM KH 2 PO4/KOH, 
1 mM DTE, pH 7.0) according to the following pro- 
gramme: 0-60 ml, 20% J; 60-90 ml, 28% J; 90-140 ml, 
28-86% J. The eluted fractions were immediately adjusted 
to 0.5 mM EGTA by preparing the test tubes with 1/1000 th 
volume of 0.5 M EGTA (pH 7.0). Fractions containing 
high activity were pooled and brought o 0.1 M NaC1, 2 
/zg/ml aprotinin and 2 /xM leupeptin. 
Step 5: Gel filtration on Superdex 200 HiLoad 16/60. 
Following hydroxylapatite chromatography II the type 3 
PtdIns 4-kinase pool was concentrated 10-fold in a Cen- 
trifree TM Micropartition System (Amicon) by centrifuging 
at 1000 × g for 20 min at 4°C. After dilution of this 
concentrate with either 10 mM Tris-HC1, 1 mM DTE, 0.1 
mM EDTA, 0.5 M NaC1 (pH 7.5), or alternatively with 10 
mM Tris-HC1, 1 mM DTE, 0.1 mM EDTA, 0.1 M NaCI, 
0.1% CHAPS (pH 7.5), the samples were applied in two 
separate runs onto a Superdex 200 HiLoad (1.6 X 60 cm, 
flow rate 30 ml/h)  pre-equilibrated with the above buffers. 
1-ml fractions were collected and supplemented with 
CHAPS to give a final concentration f 0.1% in the case of 
gel filtration without CHAPS. The column was calibrated 
with the following standards: thyroglobulin (669 kDa), 
ferritin (440 kDa), /3-amylase (200 kDa), alcohol dehydro- 
genase (150 kDa), bovine serum albumin (66 kDa). The 
exclusion volume was determined by Blue Dextran 2000. 
2.2. Test of Ptdlns kinase activity 
PtdIns 4-kinase activity was assayed at 25°C in a reac- 
tion mixture containing 0.83 mg/ml Ptdlns, 5 mM 
[T32p]ATP (400-800 Bq/nmol), 27 mM MgC12, 116 mM 
KCI, 116 mM HEPES/KOH, 1 mM EDTA, 1 mM EGTA, 
1 mM DTE and 0.4% Triton X-100 (pH 7.5). In the assays 
for K m (ATP/Mg 2+) the free [Mg 2+ ] varied between 
20-25 mM; K m values for PtdIns were calculated employ- 
ing a molecular weight of 955 for the L-palmitoyl-2- 
linoleoyl-derivative. Product formation was proven to be 
linear with time and enzyme concentration. For variation 
of all other conditions ee Vars~inyi et al. [7]. 
2.3. Renaturation of Ptdlns 4-kinases following polyacryl- 
amide gel electrophoresis in the presence of SDS 
7.5% SDS-PAGE was carried out according to Laemmli 
[30] with a reduced SDS concentration of 0.05% in the 
sample as well as in the chamber buffers. Following 
concentration by AMICON ultrafiltration, type 3 (first 
activity peak from hydroxylapatite chromatography I) and 
type 2 (eluted by Triton X-100 as a second activity peak 
from hydroxylapatite chromatography I) were applied onto 
a polyacrylamide gel (ca. 80 /xg of Ptdlns 4-kinases). 
Following electrophoresis at + 4°C, overnight races con- 
taining samples were cut into 2-mm segments and incu- 
bated overnight at +4°C by gently shaking them in 10 
volumes of renaturation buffer consisting of 10 mM Tris- 
HC1, 1 mM DTE, 0.1 mM EDTA, 0.1% CHAPS, 0.2% 
Triton X-100, 0.03% NaN 3 (pH 7.5), for type 3, and 10 
mM Tris-HCl, 1 mM DTE, 0.1 mM EDTA, 0.1% sodium 
DOC, 0.2% Triton X-100, 0.03% sodium azide (pH 7.5), 
for the type 2 isoform, respectively. Ptdlns 4-kinase activ- 
ity was assayed in supernatants. In both cases a parallel 
slot was silver-stained to detect he protein, according to 
Merril et al. [31]. 
Protein was determined using the method of Bradford 
[32] employing bovine serum albumin as standard. 
32p radioactivity was determined in the LSC SAFTY 
cocktail (Baker Chemicals, Deventer, NL). 
Free Mg 2÷ concentrations were calculated by a pro- 
gramme of R. Thieleczek using the stability constants of 
Sillen and Martell [33,34]. 
2.4. Protein sequencing 
The protein obtained in step 4 from hydroxylapatite (see 
above) was subjected to a 5% SDS-PAGE (according to 
Laemmli) and the resulting bands were electroblotted (Semi 
dry Blot, Pharmacia) onto a PVDF-membrane. The mem- 
brane part containing the 200 kDa band was cut into pieces 
and the protein was digested with modified trypsin (Boeh- 
ringer Mannheim). The resulting peptides were dissolved 
in 60% acetonitrile and in 100% formic acid. After the 
eluate had been concentrated in vacuum, the peptides were 
separated by reversed-phase HPLC on a mixed C2-C18 
column (/zRPC C2/C18 PC 3.2/3, Pharmacia) applying 
a linear acetonitrile gradient. (84% acetonitrile, v /v ,  in 
0.08% trifluoroacetic a id (TFA). UV absorption was mon- 
itored at 204 nm. Fractions with high absorbance were 
collected and re-applied onto the same column pre-equi- 
librated in 10 mM ammoniumacetate (pH 6.9). Chro- 
matography was carried out in the presence of a linear 
acetonitrile gradient (84% acetonitrile, v /v ,  in 10 mM 
ammoniumacetate, pH 6.9) according to Aebersold et al. 
[35]. Sequencing of the peptides was carried out using the 
Edman degradation method in a gas-liquid sequenator 
(Applied Biosystems 476A) according to Hewick et al. 
[361. 
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2.5. PCR 2.6. Screening of cDNA libraries 
The following primers, P2-P6, and antisense primers, 
P2a-P6a, were derived from the sequenced peptides (bold 
in Fig. 6B): 
P2: 5'-CARCARTAYACNCARGCNATGTTYAA-3', 
P2a: 5'-TTRAACATNGCYTGNGTR TAYTGYTG-3', P3: 
5'-ATGATHCARTAYTAYCARAAYGAYAT-3', P3a: 
5'-ATRTCRTTYTGRTARTAYTGDATCAT-3', P4: 5'- 
CARGGNTTGATHAAYACNTAYCC-3' ,  P4a: 5'- 
GGRTANGTRTTDATCAANCCYTG-3 ' ,  P5: 5'- 
CARATGACNGTNGARCARAA-3', P5a: 5'-YTTYT- 
GYTCTCNACNGTCATYTG-3', P6: 5'-GTNTAYTGG- 
GTNGARGA-3', P6a: 5'-YTCYTCNACCCARTANAC-3'. 
PCR was carried out [37,38] using a mixture of random- 
and oligo dT-primed first strand cDNA (cDNA Synthesis 
Kit, Gibco BRL) as a template. A thermal cycler from 
Biometra was used. The cDNA had previously been syn- 
thesized with polyA RNA isolated from bovine cortex [39]. 
The reaction mixture contained in 80/xl 0.2 /xg cDNA, 
1.25 pmol//xl sense primer, 1.25 pmol//xl anti-sense 
primer, 10 mM dNTP, 4 mM MgC12, 8 /xl TAQ-buffer 
(Perkin Elmer), 2 /xg T4 gene 32 protein (Boehringer 
Mannheim) [40,41], 5 U Ampli-TAQ (Perkin Elmer). The 
following programme was run: 96°C 180 s, (42°C 30 s 
0.82°C/s, 72°C 105 s 0.18°C/s, 96°C 45 s 0.37°C/s)'5 
cycles, (46°C 30 s 0.80°C/s, 72°C 105 s 0.87°C/s, Incre- 
ment 1 s, 96°C 45 s 0.36°C/s)" 40 cycles, 72°C 600 s. 
Twenty reaction mixtures were composed employing all 
possible primer-combinations. The reaction products were 
analyzed by agarose-gel lectrophoresis and the separated 
PCR fragments were blotted onto a positively charged 
nylon membrane (Quiabrene +, from Quiagen; Vacuum 
Blotter, Biometra, the conditions were specified by the 
manufacturer). The blots were hybridized successively with 
DIG-tailed oligonucleotides, P2-P6 (DIG Hybridization 
Manual, Boehringer Mannheim) [42]. Hybridizing PCR 
fragments were subcloned into pBluescript KS + 
(Stratagene) or pUC 19 (MBI Fermentas). 
A random primed bovine brain A gt 10 library (Clon- 
tech) and a bovine cortex oligo dT primed A ZAP library 
(Stratagene) were screened with DIG-labeled PCR frag- 
ments [43] from PIK 200 subclones as probes. The tests for 
detection were performed according to the DIG Hybridiza- 
tion Manual (Boehringer Mannheim). Inserts from positive 
plaques were subcloned into pBlueskript KS + (Strata- 
gene). 
2.7. Amplification of flanking sequencing 
Flanking sequences were obtained using nested-PCR 
with primers P17, 18 and the antisense primer P23a: 
PI7: 5'-TGCTGCCCAACGCCACCATC-3', P18: 5'- 
ACCGCCAGCCAGCTGGTTCC-3 ' ,  P23a: 5'- 
AARTARTCRTACATNCCRAARTC- 3'. 
The PCR mixture 1 contained 0.2 /xg cDNA, 0.8 
pmol//xl P17 sense primer, 1.0 pmol//zl P23a anti-sense 
primer, 10 mM dNTP, 4 mM MgC12, 6 /xl TAQ-Buffer 
(Perkin Elmer), 2 /xg T4 Gene 32 protein (Boehringer 
Mannheim), 5 U Ampli-TAQ (Perkin Elmer) in a total 
volume of 60 /xl. The following programme was em- 
ployed: 96°C 180 s, (54°C 30 s l°C/s, 72°C 120 s 
0.5°C/s, 96°C 45 s l°C/s)*5 cycles, (56°C 30 s l°C/s, 
72°C 120 s l°C/s, increment 1 s, 960C 45 s l°C/s) * 30 
cycles, 72°C 600 s. Reaction mixture 2 contained 5 /xl 
PCR 1, 0.8 pmol//xl P18 sense primer, 1.0 pmol//xl P23a 
anti-sense primer in a total volume of 60 /xl. All the other 
components were identical to mixture 1. The same pro- 
gramme was used without initial cycles. 
2.8. 3'-RACE PCR 
For 3'-RACE PCR (Gibco-BRL) [44] the sequence of 
the gene-specific sense primer, 5'-GTTGCGGGGT- 
TAGTGAGCTTG-3', was employed. The reaction mixture 
was identical to mixture 1. The following programme was 
Table 1 
Enrichment of type 3 Ptdlns 4-kinase 
Step Protein Activity Specific activity Yield Purification- 
mg nmol × min- t nmol × min- i × mg- i % fold 
1000 × g supernatant 6806 17 884 2.6 100 1 
100000 × g pellet 5175 15 927 3.1 89 1.2 
NaC1 washed membranes 3490 14 374 4.1 80 1.6 
Triton X114 solubilizate n.d. 10 365 n.d. 58 n.d. 
(Nil4)2 SO4 2539 9983 3.9 56 1.5 
Hydroxylapatite I (pt peak) 22.8 1292 22.5 7.2 8.6 
Heparin-Sepharose 1.6 762 476 4.3 183 
Hydroxylapatite II 0.69 478 693 2.7 266 
Superdex 200 0.057 167 2900 0.9 1115 
The isoform was enriched from bovine brain (starting material 120 g) as described in Section 2. The table is based on approximately 30 preparations. 
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employed: 96°C 180 s, (60°C 30 s l°C/s, 72°C 360 s 
l°C/s, increment 1 s, 96°C 45 s l°C/s) * 30, 72°C 600 s. 
2.9. Sequencing of PI4K 200-subclones 
The subcloned cDNA was sequenced with the TAQ 
Dye Terminator Kit (Applied Biosystems). Reaction prod- 
ucts were detected on an A 373 DNA sequencer (Applied 
Biosystems). Both strands from three different and inde- 
pendent subclones were sequenced to verify the results, 
thus minimizing possible ~rrors in the 3' half of the cDNA 
due to the use of Taq based PCR. 
2.10. Data processing 
Data processing was performed with the Lasergene 
Software by DNASTAR. Protein motifs were searched 
using PROSITE Database 1145]. 
3. Results 
A typical purification procedure for Ptdlns 4-kinase 
from bovine brain is summarized in Table 1. About 89% 
of the activity present in a crude extract is sedimented at 
100000 × g. From the obtained membranes less than 10% 
of the activity is released !by washing them with 150 mM 
NaCI. The enzyme can be solubilized with Triton X-114; 
after phase separation about 72% of the activity appears in 
the water phase. Already in the first step the two isoforms, 
type 3 and type 2, can easily be separated on hydroxyl- 
apatite in the presence of 0.5 M NaC1 (Fig. 1): applying a 
gradient of up to 300 mM phosphate, an activity peak is 
eluted which represents he: type 3 isoform; type 2 can only 
be eluted by including Triton X-100 in the elution buffer 
(second activity peak, Fig:. 1). The two isoforms are set 
apart by their K i values for adenosine which are 500 /xM 
15 ..0 
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Fig.  2. Heparin-Sepharose chromatography. The type 3 Ptdlns 4-kinase 
eluted from hydroxylapatite I (first peak from Fig. 1) was pooled and 
chromatographed on Heparin-Sepharose. Ptdlns 4-kinase activity ( • ) and 
protein (unbroken line) were assayed in 12-ml fractions as described in 
Section 2. The NaC1 gradient is indicated by the dashed line. 
for the type 3 and 25 /zM for the type 2 isoform. The 
respective K m values of type 3 and 2 are 730 and 210/xM 
for Ptdlns and 700 and 90 /xM for ATP/Mg 2+ (for assay 
conditions ee Section 2.2). This characterization confirms 
that the first peak contains the type 3 and the second peak 
the type 2 isoform. 
Several consecutive chromatographic steps on 
hydroxylapatite, on Heparin-Sepharose (Fig. 2), and on a 
second hydroxylapatite (Fig. 3) result in a ca. 300-fold 
purification. Finally gel filtration over Superdex 200 (Fig. 
4) yields a more than 1000-fold overall enrichment (Table 
1). SDS inhibits the type 3 isoform at 0.005% (w/v)  to an 
extent of ca. 98%. However, a combination of 0.1% 
CHAPS with 0.2% Triton X-100 almost completely over- 
comes this SDS inhibition; 90% of the residual activity can 
be assayed in the presence of these two detergents. There- 
fore, SDS-PAGE has been carried out at a reduced SDS 
concentration resulting in a final SDS concentration of 
0.005% in the renaturation assay. Using this method one 
main activity peak of the type 3 isoform can be seen, 
coinciding with a 200 kDa polypeptide (Fig. 5A). About 
20% of the activity loaded onto the gel is recovered. 
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Fig. 1. Separation of PtdIns 4-k:inase isoforms by hydroxylapatite chro- 
matography I. Triton X-114 solubilized and ammonium sulfate precipi- 
tated Ptdlns 4-kinase sample (see Section 2) was employed. Fractions of 
15 ml were collected and PtdIns 4-kinase activity (• )  was assayed. 
Protein (unbroken line) was recorded at 280 nm. The linear phosphate 
gradient is indicated by a dashed line. The arrow indicates the inclusion 
of 0.2% Triton X-100 into the elution buffer. 
50b[I "" i01 -0.2 
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Fig. 3. Hydroxalapatite chromatography II. A pool of active samples from 
Hepafin-Sepharose was chromatograpbed ona hydroxylapatite column. In 
fractions (] ml) PtdIns 4-kinase activity (• )  and protein distribution 
(unbroken line) were assayed as described in Section 2. The phosphate 
gradient profile is indicated by the dashed line. 
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Employing the same reduced SDS concentration i  SDS- 
PAGE the type 2 enzyme is inhibited only to 7%. In 
presence of 0.1% DOC and 0.2% Triton X-100 the activity 
is enhanced to 120%. Following treatment of gel slices 
with this DOC-Triton X-100 solution, a main activity peak 
appears coinciding with an apparent molecular weight of 
55 kDa (Fig. 5B). About 90% of the loaded activity can be 
recovered. The 200 kDa type 3 and the 55 kDa type 2 
Ptdlns 4-kinases are the only activities detectable in the 
Triton X-114 solubilizate of brain microsomes. 
"W 
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Fig. 4. Gel filtration of the type 3 Ptdlns 4-kinase over Superdex 200 
HiLoad. Following concentration and appropriate dilution of the type 3 
containing pool after hydroxylapatite II chromatography (see Section 2) 
the samples were applied onto a Superdex 200 HiLoad column (16//60) 
in absence ((3) and presence (×)  of CHAPS in the buffer, respectively. 
A: Ptdlns 4-kinase activity was assayed in fractions of 1 ml as described 
in Section 2. B: Silver staining of polypeptides following SDS-gele- 
lectrophoresis was carried out according to Merril et al. [31]: 200 izl of 
fractions following gel filtration in presence of CHAPS were precipitated 
by TCA, centrifuged, the pellet was dissolved in 3% SDS, 10% glycerol, 
5% 2-mercaptoethanol and electrophoresed. High molecular weight stan- 
dards from Sigma were run in parallel and the corresponding apparent 
molecular weights are indicated. 
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Fig. 5. Renaturation of Ptdlns 4-kinase activity after SDS-gele- 
lectrophoresis. Samples of the type 3 (A) and type 2 (B) Ptdlns 4-kinases 
have been prepared for a modified electrophoresis a described in Section 
2. Molecular weight standards were run in parallel as described in the 
legend of Fig. 3. Activities were determined following renaturation, as 
described in Section 2. 
Gel filtration of the native type 3 enzyme in the pres- 
ence or absence of CHAPS, independent of ionic strength 
yields an activity maximum which indicates an apparent 
molecular weight of 470-490 kDa. The activity increase 
and decrease parallels the elution of a 200 kDa polypep- 
tide, as determined by SDS-gel electrophoresis (Fig. 4). 
We therefore conclude that this 200-kDa polypeptide rep- 
resents a monomeric form of the type 3 Ptdlns 4-kinase 
which dimerizes in the native state. 
In order to identify the primary structure of this Ptdlns 
4-kinase, the 200-kDa protein was blotted onto PVDF 
membranes and the protein was digested with trypsin. The 
resulting peptides were separated and purified by HPLC 
(for experimental details see Section 2). The isolated pep- 
tides which were identified by microsequence analysis are 
shown in bold letters in Fig. 6B. 
These peptide sequences were used to construct and 
synthesize the degenerated oligonucleotides P2 to P6. PCR 
products could be obtained with these primers and first 
strand cDNA template, synthesized with polyA-RNA iso- 
lated from bovine brain cortex. The products generated by 
primers P2/P4 show one clear hybridization signal with 
P5 being used as a probe. The 812b fragment (KS 102) 
was subcloned and sequenced (Fig. 6A). The deduced 
amino acid sequence contains additional peptide sequences 
which were identified by peptide sequencing (see Fig. 6B). 
This subclone was used to synthesize hybridization probes 
which were employed to screen cDNA libraries from 
cortex and brain. In the random primed library two differ- 
ent positive clones were found (KS 1201 and KS 1201/2) 
which overlap with the clone KS 102. One 3'-flanking 
clone, pUC PCR 176, was amplified using nested PCR 
with the first strand cDNA as template; the 3'-end was 
amplified by 3'-RACE PCR, thus obtaining the clone pUC 
PCR 180. From all the clones a 4.7 kb contiguous e- 
quence was built up (Fig. 6A). The open reading frame 
covers 4.4 kb with a 0.3 kb untranslated 3'-end which 
yields a deduced amino acid sequence of 1467 amino acids 
for which a molecular weight of 166,178 is calculated. 
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KS1201/I(I>1780) 
KS1201/2(I>748) 
KSI02(I>812) 
pUCPCRI76(I>I519) 
pUCPCRI80(I>II49) 
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B 
TT CCG GTG CA{; ATC CTG CAG CAG AAA TTC TGC CAG CCC CCC TCC CCG CTT 50 
P V Q I L Q Q K F C Q P P S P L 16 
GAC GTG CTC ATC ATC GAC CAG CTG GGC TGC CTG GTC ATC ACC GGA AAC CA 100 
D V L I I D Q L G C L V I T G N Q 33 
A TAT ATT  TAC CA(; GAG GTG TGG AAC CTC TTT CAG CAG ATC AGC GTG AAG G 150 
Y I Y Q E V W N L F Q Q I S V K A 50 
CC AGC TCG GTC GTG TAC TCG GCC ACC AAG GAC TAC AAG GAC CAT GGC TAC 200 
$ S V V Y S A T K D Y K D H G Y 66 
AGG CAC TGC TCG CTG GCG GTG ATC AAC GCC CTG GCC AAC ATC GCG GGC AA 250 
R H C S L A V I N A L A N I A G N 83 
C ATC CAG GAT GAG CAC CTC GTG GAC GAG CTG CTC ATG AAC CTG CTG GAG C 300 
I Q D E H L V D E L L M N L L E L i00 
TG TTT  GTG CAG CTG GGG CTG GAG GGC AAG CGG GCC AGT GAG CGG GCC AGC 350 
F V Q L G L E G K R A S E R A 5 116 
GAG AAG GGG CCC GCC CTC AAG GCC TCC AGC AGT GCG ~ AAC CTG GGC GT 400 
E K G P A L K A S S S A G N L G V 133 
G CTC ATC CCT GTG ATC GCA GTG CTC ACC CGG CGG CTG CCG CCC ATC AAG G 450 
L I P V I A V L T R R L P P I K E 150 
AG CCG AAG CCG AGG CTG CAG AAG CTC CTC CGG GAC TTC GGG CTG TAC TCG 500 
P K P R L Q K L L R D F G L Y S 166 
GTG CTG ATG C-GG TTC GCC GTG GAG GGC TCA GGA CTC TGG CCC GAG GAG TG 550 
V L M G F A V E G S G L W P E E W 183 
G TAC GAG GGG GTC TGT GAC ATC C-CC ACC AAG TCC CCG CTG CTC ACC TTT C 600 
Y E G V C D I A T K 5 P L L T F P 200 
CC AC-C AAA GAG CCT CTG CGG TCC GTC CTC CAG TAC AAC TCG GCC ATG AAG 650 
S K E P L R S V L Q Y N S A M K 216 
AAC GAC ACG GTT ACG CCT GCC GAG C~G AGT GAG CTG CC-C AGC ACC ATC GT 700 
N D T V T P A E L S E L R S T I V 233 
C AAC CTT CTG GAC CCG GCC CCC GAG GTG TCC GCC CTC ATC GGC AAG CTG G 750 
N L L D 9 A P E V S A L I G K L D 250 
AC TTC GCC ATG TCC ACC TAC CTG CTG TCC GTC TAC CGG CTG GAG TAC ATG 800 
F A M S T Y L L S V Y R L E Y M 266 
AGG GTC CTG CGC TCC AGC GAC CCC GCC CGC TTC CAG GTG ATG TTC TGC TA 850 
R V L R 5 S D P A R F Q V M F C Y 283 
C TTC GAG GAC AAG GCC ATC CAG AAG GAC AAG TCC GGG ATG ATG CAG TGT G 900 
F E D K A I Q K D K S G M M Q C V 300 
TG ATC GCC GTC GCC GAC AAG GTG TTC GAC GCC TTC CTG AAC ATG ATG GCG 950 
I A V A D K V F A A F L N M M A 316 
GAG AAA GCC AAG ACC AAG GAG AAC C4kG GAG GAG CTG GAG CGG CAC GCG CA 10O0 
E K A K T K E N E E E L E R H A Q 333 
G TTC CTG CTG GTC AGC TTC AAC CAC GTC CAC IsAG CGC ATC CGC AGG GTC G 1050 
F L L V S F N H V H K R I R R V A 350 
CC GAC AAG TAC CTG TCT GGG CTG GTG GAC AAG TTC CCC CAC TTG CTC TGG 1100 
D K Y L S G L V D K F P H L L W 366 
AGC GGG ACG GTG CTG GAG ACC ATG CTG GAC ATC CTG CAG ACC CTG TCC CT 1150 
S G T V L E T M L D I L Q T L S L 383 
G TCG CTG AGT GCT GAC ATC CAC AAG GAC CAG CCA TAC TAC GAC ATT  CCC G 1200 
5 L S A D I H K D Q P Y Y D I P D 400 
AC GTG CCC TAC CGC ATC ACC GTC CCG GAC ACC TAC GAG GCC CGA GAG AGC 1250 
V P Y R I T V P D T Y E A R E 5 416 
ATC GTC AAA GAC TTC GCC GCG CGC TGC GGG ATG ATC CTT CAG GAG GCC AT  1300 
I V K D F A A R C G M I L Q E A M 433 
G AAG TGG GCG CCC ACG GTC ACC AAG TCC CAC CTG CAG GAG TAC CTG AGC A 1350 
K W A P T V T K S H L Q E Y L S K 450 
AG CAC CAG AAC TGG GTA TCG GGG CTG TCG CAG CAC ACG GGG CTG GCC ATG 1400 
H Q N W V 5 G L S Q H T G L A M 466 
GCC ACC GAG AGC GTC CTG CAC TAC GCC GGC TAC AAC AAG CAG AGC ACG AG 1450 
A T E S V L H Y A @ Y N M Q 5 T S 483 
C CTC GGG GCG ACA CAG CTC ACA GAA CGG CGG GCC TGT GTC AAG AAG GAC T 1500 
L G A T Q L T E R R A C V K K D Y 500 
AC TCC AAC TTC ATG GCT TCC CTG A~C CTG CGC AAC CGC TAT GCG GGC GAG 1550 
S N F M A S L N L R N R Y A G E 516 
GTG TAC GGG ATG ATC CGG TTC TCG GAC GCC ACA GGC CAC ACA TCG GAC CT 1600 
V Y G M I R F S 0 A T G H T S D L 533 
G AAC AAG ATG ATG GTC CAG GAG CTG AAG GCT GCG CTG GGC GCC GGC GAC G 1650 
N K M M V Q E L K A A L G A G D A 550 
CT  CAG CAG TAC ACG CAG GCC ATG TTC AAG CTG ACG GCC ATG CTC ATC AGC 1700 
Q Q • T Q A M F K L T A M L I S 566 
AGC AGA GAC TGT GAC CCG CAG CTC CTC CAC CAC CTG TGC TGG GGC CCC CT 1750 
S R D C D P Q L 1 H H L C W G P L 583 
GCAGATGTTC~CGAGCAC~ATGGAGACC~CCTG~CT~T~GAGTI800  
Q M F N E H G M E T A L A C W E W 6 8 0  
CTG CTG GCC ~ ~ ~C ~ GTG G~ GTG CCG TTC ATG C~ GAG ATG 1850 
L L A G K N G V E V P F M R E M  616 
~G~G~CT~CAGATGACCGTGGAGCAG~GTTC~CTGTTTTCT~I900 
A G A W Q M T V E Q K F G L F S A 6 3 3  
G G A G A T G ~ G G ~ A G A C C C C T T G ~ C ~ A T C A G ~ C A G T ~ G C C C A I 9 5 0  
E M K E A D P L A A S E A S Q P K 6 5 0  
~CCGTGT~CCCCGAGGTGACCCCTCACTACATCT~ATC~CTTCCTG2000 
P C A P E V T E H Y I W I D F L  666 
GTA~GC~TTTGAGATT~C~GTACT~AGTTCCGACCAGGTG~GAT2050 
V Q R F E I A K Y C S S D Q V E I 6 8 3  
C TTC T~ AM CTC CTG CAG CGC TCC CTG TCC CTG A~ ATC ~ ~ ACC G 2100 
F C S L L Q R S L S L S I G G T A 7 0 0  
CG~CA~ATG~CC~CATGTG~G~CATC~CCCC~TTC~GCTG2150 
G S M N R H V A A I G P R F K L  716 
CTG ACC CTC ~ CTG TCC CTG CTG CAC ~G GAC GTG CTG CCC ~C ~C AC 2200 
L T L G L S L L H A D V L P N A T 7 3 3  
CATCC~CGTGCTCC~G~GATCTACTCCACCGCCTTT~CTACT2250 
I R N V L R E K I Y S T A F D Y F 7 5 0  
TC AGC TGC CCG CCG A~ TTC CCG ACC CAG ~ GAG ~G AGG CTG CGT GAG 2308 
S C P P R F P T Q G E K R L R E  766 
GAC ATC AGC GTG ATG ATC ~G TTC T~ ACC ~A ATG TTC TCA GAC ~G ~ 2350 
D I S V M I K F W T A M E S D K K 7 8 3  
G TAC CTG ACC GCC AGC ~G CTC GTT CCC CCA GAC ~C CAG GAC ACC CGG A 2400 
Y L T A S Q L V P P D N Q D T R 5 8 0 0  
~C CTG GAC ATC GCG GTC ~C TCT CGC CAG CAG ~C ACG CAG ~ TGG 2450 
N L D I A V G S R Q Q A T Q G W  816 
ATC ~C ACG TAC CCG CTG TCC A~ ~C ATG TCC ACC ATC TCC ~G ~ TC 2500 
I N T Y P L S S G M S T I S K K S 8 3 3  
GG~ATGTCC~G~GACC~CC~CTCCCAGCTGCAC~GTATTACA2550 
G M S K K T N R G S Q L H K Y Y M 8 5 0  
TG~G CGC C~ACG CTG CTG CTG TCA CTG CTG ~C ACC GAG ATC GAG C~ 2600 
K R R T L L L S L L A T E I E R  866 
CTCATCACCT~TAC~CCCGCTGTCC~CCCGGAGCTGGAGCTGGACCA2650 
L I T W Y N P L S A P E L E L D Q 8 8 3  
G ~ G ~ G ~ A ~ G T G ~ C ~ C T ~ A ~ T C C ~ G T A C A T C ~ C T G A 2 7 0 0  
A G E S S V A N W R S K Y I S L S 9 0 0  
~GAG~GCAGT~GGAC~CGTG~CCTC~CTGGA~ATCTCGCCC2750 
E K Q W K D N V N L A W S I S P  916 
~CCTG~CGTGCAGCTGCCAGCCAGGTTC~G~CACGGAG~TATC~2800 
H L A V Q L P A R F K N T E A Z G 9 3 3  
C~CGAGGTGACACGTCTGGTGC~TTGGACCCA~AGCCGTTAGTGACG2850 
N E V T R L V R L D P G A V S D V 9 5 0  
TCCCG~CATC~GTTCCTGGTCACCT~CACACCATCGAC~CGAC2900 
P E A I K F L V T W H T I D A D  966 
~CCCCGAGCTCA~CGTGCTGT~T~GCCC~GGACCCACCCAC2950 
A P E L S H V L C W A P A D P P T 9 8 3  
A ~C CTG TCC TAC TTC TCC A~ ATG TAC CCG CCG ~C CCC CTC ACG ~G C 3000 
G L S Y E S S M Y P P H P L T A Q I 0 0 0  
AGTAC~GTC~GGTCCTGA~TCCTTTCCGCCGGAC~CATCCTGTTC3050 
Y G V K V L R S F P P D A I L E I 0 1 6  
TACATTCCCCAGATTGTGCAG~GCTCAGGTATGAC~GATG~TACGT3100 
Y I P Q I V Q A L R Y D K M G Y V I 0 3 3  
GC~GAGTACATCCTGT~C~CTCCCAGTCCCAGCTACTG~A~CC3150 
R E Y I L W A A S Q S Q L L A H Q I 0 5 0  
A G T T C A T C T ~ C A T G ~ G A C C ~ C A T C T A C G T G G A C ~ G ~ C A C 3 2 0 0  
F I W N M K T N I Y V D E E G H I 0 6 6  
CAG~G~CCCCGACATC~TGACCTCCTGGAGCAGCTGGTGGAGGAGAT3250 
Q K D P D I G D L L E Q L V E E I I 0 8 3  
CACA~TCCCTCTCC~CCCG~C~GGACTTCTACCAGC~G~TTCG3300 
T G S L S G P A K D F Y Q R E F D I I 0 0  
AC TTT TTC ~C ~G ATC ACC ~C GTG TCG GCC ATC ATC ~ CCC TAC CCC 3350 
F F N K I T N V S A I I K P Y P I I I 6  
~ G A C G A G A ~ G ~ G ~ C T ~ C T G T C G ~ C T T G T C T G ~ G T G ~ 3 4 0 0  
K G D E R K K A C L S A L S E V K 1 1 3 3  
G GTG CAG CCT ~ T~ TAC CTG CCC A~ ~C CCC GAG GCC ATC GTG CTG G 3450 
V Q E G C Y L P S N P E A I V L D I I 5 0  
ACATCGACTAC~GTCT~GACGCCCATGCAGAGT~C~C~GGCCCCG3500 
I D Y K S G T P M Q S A A K A g I 1 6 6  
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TAT CTG GCG AAG TTC AAG GTG ~ CGT TGC GGG GTT AGT GAG CTT GAG AA 3550 GC AAC CTC GGC TGG GAG CCG GAC ATC ~-~G CTG ACG GAC GAG ATG GTG ATG 4100 
Y L A K F K V K R C G V S E L E K 1183 N L G W E P D I K L T D E M V M 1366 
G GAA GGC CTG CGG TGC CGC TCA GAC CCC GAG GAG GAG GGC AGC ATG CAG G 3600 ATC ATG GGG GGC AAG ATG GAG GCC ACG CCC TTC AAG TGG TTC ATG GAG AT  4150 
E G L R C R S D P E E E G 5 M Q E 1200 I M G G K M E A T P F K W F M E M 1383 
AG GCC GAC GGC CAG AAG ATC TCC TGG CAG GCG GCC ATC TTC AAA GTG GGG 3650 G TGT GTC CGT C-GC TAC CTG GCT GTG CGG CCC TAC ATG GAC GCT GTG GTC T 4200 
A D G Q K I S W 0 A A I F K V G 1216 C V R G Y L A V R P Y M D A V V S 1400 
GGC GAC TGC CGG CAG GAC ATG CTG GCC CTG CAG ATC ATC GAC CTC TTC AA 3700 CT CTG GTC ACT CTC ATG CTG GAC ACG GGC CTG CCC TGC TTC CGT GGC CAG 4250 
G D C R Q D M L A L Q I I D L F K 1233 L V T L M L D T G L P C F R G Q 1416 
A AAC ATC TTC CAG CTG GTC GGC CTG GAC CTC TTC GTC TTC CCG TAC CGG G 3750 ACA ATC AAG CTC CTC AAG CAC AGG TTC AGC CCC AAC ATG ACG GAG CGA GA 4300 
N I F Q L V G L D L F V F P Y R V 1250 T I M L L K H R F S P N M T E R E 1433 
TG GTG GCC ACC GCC CCC GGG TGC GGC GTC ATC GAG TGC ATC CCC GAC TGC 3800 G GCC GCG AAC TTC ATC CTG AAG GTC ATT  CAG AGC TGC TTC CTC AGC AAC A 4350 
V A T A P G C G V I E C I P D C 1266 A A N F I L K V I Q S C F L S N R 1450 
ACC TCC CGG GAC CAG CTG GGC CGC CAG ACC GAC TTC GGC ATG TAC GAC TA 3850 GG AGC CGG ACC TAC GAC ATG ATC CAG TAC TAT CAG AAC GAC ATC CCC TAC 4400 
T S R D Q L G R Q T D F G M Y D Y 1283 S R T Y D M I Q Y Y Q N D I P Y 1466 
C TTC ACG CGC CAG TAC GGG GAC GAG TCC ACA CTG GCC TTC CAG CAG GCG C 3900 TGA GGG CGG GGC GGC CGC AAT CAA GCT CCG CAG GCG AGC AGG CCG CCG CT 4450 
F T R Q Y G D E S T L A F Q Q A R 1300 Stop 
GC TAC AAC TTC ATC CGC AGC ATG GCC GCC TAC AGC CTC CTC CTG TTC CTG 3950 T CAT  CCG AGG ACA AAT GGG CTG GAG GTG CCC CTG CCA AGC CGG AGA CGC A 4500 
Y N F I R S M A A Y S L L L F L 1316 CG GTC CCG GGT GCC GCC CGT GTG GCC AGA AGG AYA ATC AGA GCC GGT CTC 4550 
CTG CAG ATC AAG GAC CGG CAC AAC GGC AAC ATC ATG CTG GAT AAG AAG GG 4000 TGT GTG GGC ACG GGC TCT TCT GCA CTG GAC ACA TTT CCC CCC CCC CGT CC 4600 
L Q I M D R H N G N I M L D K K G 1333 T GTC TCA GAG GTA CAG GGA GCA CGT TCT TAG GCA CAA AAA TCA GAA CAG T 4650 
C CAC CTC ATC CAC ATC GAT TTC GGC TTC ATG TTC GAA AGC TCC CCG GGC G 4050 GG TAT TTA ACC AAC GTG AGC AAA ATA AAA ACA AAA 4685 
H L I H I D F G F M F E S S P G G 1350 
Fig. 6. A: Clonemap ofPI4K200. The first dashed line represents the contiguous sequence, enlarged dashed lines indicate overlapping clones. B: cDNA 
and deduced amino acid sequence ofPI4K200. The amino acid sequence in single-lettered code is indicated below the nucleotide s quence. Sequenced 
peptides are bold. Oligonucleotides derived from peptides for PCR are underlined. The cDNA sequence is reported including the non-coding region up to 
base 4685; downstream the sequence has not yet been refined. 
Based on homology, the C-terminal part of this se- 
quence obviously represents the catalytic domain of this 
type 3 Ptdlns kinase. Sequence alignment of about the last 
300 amino acids with the corresponding domains of the 
mammalian counterpart PI4K a, the yeast enzymes STT4 
and PIK1 as well as with catalytic domains of the bovine, 
human, mouse and yeast Ptdlns 3-kinases reveals a high 
degree of sequence identity (Fig. 7). 26 of these approxi- 
mately 300 amino acids are invariable in all of these eight 
catalytic domains. The histogram shown in Fig. 7 demon- 
strates that a consensus equence can be built from all 
eight sequences. The greatest similarity of approximately 
98% is found between the bovine PI4K200 and the human 
PI4Ka.  The yeast kinase STT4 is approximately 20% 
more similar to the bovine enzyme than the yeast enzyme 
PIK1. The degree of similarity of the catalytic domains of 
all the Ptdlns 3-kinases is in the same range as that of 
PIK1 (not shown). 
Two leucine zipper motifs (amino acids 358-386 and 
862-882) are detectable, one located near one of the two 
nuclear localization signals (amino acids 345-349 and 838- 
854) [46]. Furthermore, a helix loop helix motif (amino 
acids 716-729) as found in DNA binding proteins is 
observed. Many potential phosphorylation sites for 
cAMP/cGMP-dependent protein kinases, casein kinase 2, 
protein kinase C as well as protein tyrosine kinases can be 
localized. 
4. Discussion 
Ptdlns 4-kinase activity has been found to be enriched 
with brain microsomes consistent with the observations 
made by Endemann et al. [15]. This lipid kinase activity is 
still associated with the membranes ven in the presence of 
salt, but it can be solubilized and transferred into the water 
phase following Triton X-114 treatment. Indeed, the en- 
zyme contains a-helical hydrophobic regions which can 
potentially cause membrane association (not shown). How- 
ever, once the enzyme has been transferred into the water 
phase, it no longer requires the presence of detergents. The 
dimeric form (see below) is apparently stable in aqueous 
solution. 
It has been reported that type 3 Ptdlns 4-kinase sedi- 
ments faster than /3-amylase and slower than apoferritin, 
indicating a M r between 200 and 443 kDa [15]. The results 
reported here yield a slightly higher apparent molecular 
weight of 470-490 kDa both in the absence and presence 
of CHAPS (see Fig. 4). So far, the polypeptide harboring 
the type 3 activity has not yet been identified. When 
employing our newly developed renaturation procedure in 
presence of CHAPS and Triton X-100, a 200 kDa protein 
exhibits type 3 enzymic activity. Thus, the native enzyme 
might be a dimer and this association is apparently not 
reversed by CHAPS. 
Enzyme purification, as employed here (see Table 1), 
has enriched the enzyme approximately 1000-fold. In the 
preparation gained from gel filtration, the 200 kDa band 
which has so far been identified as type 3 Ptdlns 4-kinase, 
represents on average 3% of the protein as determined by 
SDS-PAGE. Thus, the enzyme has been purified to an 
extent of approximately 30000-fold. Indeed, this protein 
band could still be composed of more than one polypep- 
tide. However, all of the peptide sequences found and 
reported here originate from one protein which was con- 
firmed by cDNA sequencing. Thus, this band seems to 
represent a homogeneous protein, namely the type 3 Ptdlns 
4-kinase. 
The cDNA sequence determined until now yields a 
molecular weight of 166,742 for the deduced amino acid 
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sequence, which is lower than the experimentally deter- 
mined molecular weight of 200 kDa. Indeed, no Kozak 
consensus sequence has been found upstream of the upper- 
most methionine [47]. The N-terminus is blocked (not 
shown), so that no unequivocal assignment of the start 
codon is possible. Thus a small part of the sequence might 
still be missing. 
The activity profile following SDS-gel electrophoresis 
which identifies the 200 kDa protein as a type 3 Ptdlns 
4-kinase agrees with the localization of a catalytic domain 
on this protein. The approximately 300 C-terminal amino 
acids not only share a high degree of similarity with the 
human type 2 PI4K c~, as was expected, but surprisingly 
they are nearly completely identical. As has already been 
reported, this domain shows a high degree of sequence 
identity to the corresponding yeast counterparts and, to a 
lesser degree, to the catalytic domains of the Ptdlns 3- 
kinases (not shown). Furthermore, sequence motifs charac- 
teristic of protein kinases can clearly be identified in the 
catalytic domain of lipid kinases. In fact, there is a con- 
served aspartate-phenylalanine-glycine motif, as well as 
aspartate, asparagine and lysine residues located l 1, 18 
and 122 residues upstream, respectively. Most of these 
conserved positions were shown to be essential for ex- 
pressing catalytic activity of lipid kinases, too [48]. 
The part of the sequence (aa 600-1100) preceding the 
catalytic domain of the human PI4Ka is also nearly 
identical to that of the bovine sequence. The surprisingly 
high degree of conservation i dicates that an important 
function is also residing in this part of the molecule. The 
difference in properties of the type 3 and type 2 isoforms 
can now be assigned to the N-terminal part of the type 3 
Ptdlns 4-kinase which is not present in the corresponding 
human type 2 PI4K ce [23]. A Northern blot of human 
tissue reveals two transcripts of 7.5 and 3.2 kb. Indeed, a 
stronger signal is found for the 7.5 kb band than for the 3.2 
kb material [23]. Alternative splicing does not necessarily 
occur identically in two different species [49], however, 
the almost identical amino acid sequences of human type 2 
PI4K a and bovine type 3 PI4K200 strongly indicate that 
these two forms might have been produced in human 
tissue by alternative splicing. Enzymologically a 97 kDa 
form corresponding in size to the human PI4K a cannot be 
detected in bovine tissue (compare Figs. 1 and 5); more- 
over, no cDNA clone containing a sequence similar to the 
5' non-coding region of PI4Kt~ was found. Thus, if 
indeed alternative splicing occurs in bovine as in human 
tissue, the product corresponding toPI4K c~ is most proba- 
bly a very minor component. 
The N-terminal part present in type 3, but not in type 2 
Ptdlns 4-kinase, may play a modulatory role in this type 3 
enzyme or is responsible for localization in special com- 
partments. Interestingly, one of two leucine zipper motifs 
is located in this N-terminal part which exceeds the type 2 
PI4K c~. Both zipper motifs can clearly be identified in the 
sequence. Leucine zippers have been found in a number of 
eukaryotic DNA binding proteins that act as transcription 
factors [50]. Binding to DNA requires dimerization via the 
two helices which expose leucine side chains on one side 
and the presence of adjacent basic regions. However, the 
adjacent stretches in the PI4K200 sequence only contain a 
few basic residues. Similarly, a helix loop helix motif-also 
identified in the PI4K200 sequence-binds to DNA as a 
dimer via adjacent basic regions. On the other hand, these 
basic regions are absent in the PI4K200 sequence. A whole 
class of proteins contains the helix loop helix motif but 
lacks an adjacent basic domain and is thought o inhibit 
transcriptional ctivation by forming heterodimers with 
proteins containing the basic helix loop helix motif [51]. 
However, whether this enzyme is indeed transported into 
the nucleus, as suggested by the presence of the two 
nuclear localization signals, remains to be shown. 
Cells overexpressing a growth factor receptor stimulate 
Ptdlns 4-kinase when treated with an agonist, suggesting 
that this enzyme is potentially regulated by tyrosine phos- 
phorylation. This observation is in line with several other 
reports, indicating tyrosine phosphorylation f the type 3 
isoform. An analysis of the sequence reveals four potential 
tyrosine phosphorylation sites for which a fairly good 
consensus equence has been found. Further studies are 
clearly required to clarify this conundrum. 
The situation regarding other protein kinases is similar. 
It has been suggested that both, cAMP-dependent protein 
kinase and protein kinase C, are involved in regulating the 
type 3 Ptdlns 4-kinase activity (for review, see Ref. [4]). In 
the sequence reported here, several potential target sites for 
these two protein kinases can be identified (see Fig. 7). 
Furthermore, there are several putative phosphorylation 
sites for casein kinase II. The identification of potential 
phosphorylation sites should facilitate the localization of 
actual phosphorylation sites employed in the living cell. 
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